Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;130(6):678-685.
doi: 10.1080/13813455.2023.2258559. Epub 2023 Nov 3.

Berberine-induced glucagon-like peptide-1 and its mechanism for controlling type 2 diabetes mellitus: a comprehensive pathway review

Mostafa Araj-Khodaei  1 , Mohammad Hossein Ayati  2   3 , Akbar Azizi Zeinalhajlou  4 , Tannaz Novinbahador  5   6 , Mehdi Yousefi  7 , Mahdi Shiri  8 , Ata Mahmoodpoor  9 , Ali Shamekh  10 , Nazli Namazi  3   11 , Sarvin Sanaie  12
Affiliations
Review

Berberine-induced glucagon-like peptide-1 and its mechanism for controlling type 2 diabetes mellitus: a comprehensive pathway review

Mostafa Araj-Khodaei et al. Arch Physiol Biochem. 2024 Dec.

Abstract

Introduction: A growing number of studies have thus far showed the association between type 2 diabetes mellitus (DM) and the intestinal microbiome homoeostasis. As reported, the gut microflora can be significantly different in patients with type 2 DM (T2DM) compared to those in healthy individuals.

Methods: The authors collected the relevant articles published until 2022 and these are carefully selected from three scientific databases based on keywords.

Discussion: This review highlights research on the anti-diabetic properties of berberine (BBR)-induced glucagon-like peptide-1 (GLP-1), as a glucose-lowering factor and a balance regulator in the microbial flora of the intestines, which plays an important role in adjusting the signalling pathways affecting insulin secretion.

Results: Considering the anti-diabetic characteristics of the BBR-induced GLP-1, BBR makes a promising complementary treatment for reducing the clinical symptoms of DM by reducing the hyperglycaemia. Berberin might be a safe and effective drug for T2DM with little or no adverse effects.

Keywords: Type 2 diabetes mellitus; berberine; glucagon-like peptide-1; gut microbiota; intestinal microbiome.

Plain language summary

Berberine induces GLP-1 insulin secretion by PLC2 pathway in the intestinalBerberine-induced GLP-1 decreases mitochondrial stress and relocates cytochrome c out of the mitochondria.Berberine induces GLP-1 secretion in the intestine by altering the bacterial profile, thus could possibly lighten diabetes symptomsBerberine-induced SCFA production, SCFA causes GLP-1 secretion from the intestinal L-Cell.Preventing mitochondrial damage, reducing adipose tissue fat, and reducing oxidative stress are thus among the results of BBR-induced GLP-1.The lower costs of BBR, and its limited side effects and higher availability, make it a promising supplementary medicine for DM.

PubMed Disclaimer

MeSH terms

LinkOut - more resources